ENTPD1 and non-small cell lung carcinoma: CD39 is known to be highly expressed in stromal, endothelial, and infiltrating immune cells of several tumor types, including non–small cell lung cancer (NSCLC), advanced pancreatic ductal adenocarcinoma (PDAC), renal cell carcinoma, and breast cancer (3, 5–11).